Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers

Transfusion

Volumn 54, Issue 4, 2014, Pages 1081-1087

  Hosing, Chitra ^a   Saliba, Rima M ^a   Hamerschlak, Nelson ^b   Kutner, Jose Mauro ^b   Sakashita, Araci Massami ^b   Kondo, Andrea Tiemi ^b   Rodrigues, Morgani ^b   Fernande, Juliana Folloni ^b   Chiattone, Alexandre ^a   Chiattone, Viviane C ^a   Barros, Jose C ^c   Chiattone, Carlos S ^c   Chiattone, Ricardo ^c   Popat, Uday ^a   Qazilbash, Muzaffar ^a   Tang, Xiao Wen ^d   Wu, Depei ^d   Majilis, Alejandro ^e   De Lima, Marcos ^f   Anguita, Timoleon ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e UNIVERSIDAD DEL DESARROLLO   (Chile)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; APHERESIS; ARTICLE; BLOOD DONOR; BLOOD VOLUME; BODY WEIGHT; CALCULATION; CD34 SELECTION; HUMAN; MEASUREMENT ACCURACY; PERIPHERAL BLOOD STEM CELL; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BLOOD CELL COUNT; BLOOD DONORS; BLOOD VOLUME; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84898915077     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12435     Document Type: Article

References (19)

1. Rajkumar SV,. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 78-88.
2. Harousseau JL, Moreau P,. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360: 2645-2654.
3. Nieto Y, Popat U, Anderlini P, et al. Autologous stem-cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013; 19: 410-417.
4. Blanes M, de la Rubia J,. Role of autologous bone marrow transplant in multiple myeloma. Curr Opin Oncol 2012; 24: 733-741.
5. van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
6. Pesek G, Cottler-Fox M,. Hematopoietic stem cell mobilization: a clinical protocol. Methods Mol Biol 2012; 904: 69-77.
7. Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507-512. (Pubitemid 27203941)
8. Gertz MA, Wolf RC, Micallef IN, et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45: 1396-1403.
9. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719-724.
10. Ford CD, Pace N, Lehman C,. Factors affecting the efficiency of collection of CD34-positive peripheral blood cells by a blood cell separator. Transfusion 1998; 38: 1046-1050. (Pubitemid 28549006)
11. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-723.
12. Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335-337.
13. Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008; 112: 2092-2100.
14. Humpe A, Riggert J, Munzel U, et al. A prospective, randomized, sequential, crossover trial of large-volume versus normal-volume leukapheresis procedures: effect on progenitor cells and engraftment. Transfusion 1999; 39: 1120-1127. (Pubitemid 29485329)
15. Trickett AE, Smith S, Kwan YL,. Accurate calculation of blood volume to be processed by apheresis to achieve target CD34+ cell numbers for PBPC transplantation. Cytotherapy 2001; 3: 5-10. (Pubitemid 32466085)
16. Pierelli L, Maresca M, Piccirillo N, et al. Accurate prediction of autologous stem cell apheresis yields using a double variable-dependent method assures systematic efficiency control of continuous flow collection procedures. Vox Sang 2006; 91: 126-134. (Pubitemid 44126608)
17. Cottler-Fox MH, Lapidot T, Petit I, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003; 419-437.
18. Rosenbaum ER, O'Connell B, Cottler-Fox M,. Validation of a formula for predicting daily CD34(+) cell collection by leukapheresis. Cytotherapy 2012; 14: 461-466.
19. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.